Arcutis Biotherapeutics, Inc. (ARQT)
Stock Price:
$21.25 USD
0.33 (1.58%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
915.66M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-90.47M |
| Shares Out |
43.09M |
| EPS (ttm) |
-10.27 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 27, 2020 |
| Last Price |
$21.25 |
| Previous Close |
$20.92 |
| Change ($) |
0.33 |
| Change (%) |
1.58% |
| Day's Open |
20.92 |
| Day's Range |
20.72 - 21.47 |
| Day's Volume |
149,058 |
| 52-Week Range |
17.10 - 40.88 |
More Stats
| Market Cap |
915.66M |
| Enterprise Value |
695.38M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
43.09M |
| Float |
21.47M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-10.27 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.56M |
| Short Ratio |
3.41 |
| Short % of Float |
7.27% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
4.75 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
-90.47M |
| Free Cash Flow |
n/a |
| Net Cash |
220.29M |
| Net Cash / Share |
5.11 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-42.53% |
| ROE |
-74.61% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (5)
| Buy |
4 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$46.40*
(118.35% upside)
Low
34.0
Current: $21.25
High
55.0
Target: 46.40
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | - | - | - |
| Operating Income | -43.13 | -19.74 | -4.11 |
| Net Income | -42.00 | -19.26 | -4.98 |
| Shares Outstanding | 1.84 | 1.24 | 0.70 |
| Earnings Per Share | -22.78 | -15.53 | -7.16 |
| Operating Cash Flow | -42.84 | -14.09 | -3.78 |
| Capital Expenditures | -0.30 | - | - |
| Free Cash Flow | -43.13 | -14.09 | -3.78 |
| Cash & Equivalents | 101 | 50.94 | 3.42 |
| Total Debt | 0.31 | - | - |
| Net Cash / Debt | 101 | 50.94 | 3.42 |
| Assets | 107 | 51.10 | 3.82 |
| Liabilities | 5.55 | 2.83 | 1.66 |
| Book Value | -65.03 | -23.99 | -4.99 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Arcutis Biotherapeutics, Inc. |
| Country |
United States |
| Employees |
49 |
| CEO |
Todd Franklin Watanabe |
Stock Information
| Ticker Symbol |
ARQT |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ARQT |
| IPO Date |
January 31, 2020 |
Description
Arcutis Biotherapeutics, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical cream formulation of roflumilast that is in Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of ARQ-151 for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was founded in 2016 and is headquartered in Westlake Village, California.